Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2023 Earnings Results

Catalyst Pharmaceuticals Beats on EPS, Stock Up 0.63%

Catalyst Pharmaceuticals reported a strong earnings per share, exceeding expectations significantly. The stock reacted positively, rising by 0.63%. However, the lack of revenue data and guidance leaves some uncertainty about future performance and growth prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.41	N/A	+34.87%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the earnings results, particularly the EPS beat. They emphasized their commitment to shareholder value.

We are pleased with our EPS performance this quarter.

Our focus remains on delivering value to our shareholders.

Catalyst Pharmaceuticals Beats on EPS, Stock Up 0.63%

Key numbers

Management commentary

Catalyst Pharmaceuticals, Inc.

More earnings this week

Catalyst Pharmaceuticals Beats on EPS, Stock Up 0.63%

Key numbers

Management commentary